Literature DB >> 1882441

Cytokines and the Koch phenomenon.

G A Rook1, R al Attiyah.   

Abstract

We outline the mechanisms contributing to the human form of the Koch phenomenon, which we define as necrosis occurring within 24-48 h of injection of mycobacterial antigen into the skin of past or present tuberculosis patients. It is probable that tissue damage mediated in the same way occurs in the lesions themselves. We suggest that the necrosis is mediated in part by cytokines, particularly Tumour Necrosis Factor (TNF), and that this occurs for three reasons. First, Mycobacterium tuberculosis evokes an immunoregulatory abnormality characterised by raised agalactosyl IgG. This abnormality, also found in rheumatoid arthritis, Crohn's disease, and Erythema Nodosum Leprosum, seems to be associated with dysregulation of cytokine release. Secondly, M. tuberculosis itself triggers further cytokine release. Thirdly, the normally protective role of TNF is distorted by several interacting properties of components of M. tuberculosis, which render the cytokine toxic to the host tissues. The immunoregulatory abnormality may be susceptible to correction by immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1882441     DOI: 10.1016/0041-3879(91)90019-o

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  17 in total

Review 1.  Tuberculous meningitis.

Authors:  G Thwaites; T T Chau; N T Mai; F Drobniewski; K McAdam; J Farrar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

2.  Intragranulomatous necrosis in pulmonary granulomas is not related to resistance against Mycobacterium tuberculosis infection in experimental murine models induced by aerosol.

Authors:  Evelyn Guirado; Sergi Gordillo; Olga Gil; Jorge Díaz; Gustavo Tapia; Cristina Vilaplana; Vicenç Ausina; Pere-Joan Cardona
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

Review 3.  Cordelia, Goneril and the febrile response.

Authors:  P A Mackowiak
Journal:  Trans Am Clin Climatol Assoc       Date:  1997

4.  Re-emergence of tuberculosis.

Authors:  J M Grange
Journal:  BMJ       Date:  1993-02-20

5.  Skin test performed with highly purified Mycobacterium tuberculosis recombinant protein triggers tuberculin shock in infected guinea pigs.

Authors:  Stephen T Reece; Nicole Stride; Pamela Ovendale; Steven G Reed; Antonio Campos-Neto
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 6.  n-3 Fatty acids uniquely affect anti-microbial resistance and immune cell plasma membrane organization.

Authors:  David N McMurray; Diana L Bonilla; Robert S Chapkin
Journal:  Chem Phys Lipids       Date:  2011-07-20       Impact factor: 3.329

7.  Ineffective cellular immune response associated with T-cell apoptosis in susceptible Mycobacterium bovis BCG-infected mice.

Authors:  L Kremer; J Estaquier; I Wolowczuk; F Biet; J C Ameisen; C Locht
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

8.  Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy.

Authors:  P J Converse; A M Dannenberg; T Shigenaga; D N McMurray; S W Phalen; J L Stanford; G A Rook; T Koru-Sengul; H Abbey; J E Estep; M L Pitt
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

9.  Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis.

Authors:  Evelyn Guirado; Olga Gil; Neus Cáceres; Mahavir Singh; Cristina Vilaplana; Pere-Joan Cardona
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

10.  Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions.

Authors:  S Khanolkar-Young; N Rayment; P M Brickell; D R Katz; S Vinayakumar; M J Colston; D N Lockwood
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.